Polina Stepensky

New Capabilities

As of May 2026: Co-inventor of NXC-201; leads ongoing Israeli trial arm

Immix Biopharma reported Thursday that 19 of 20 patients in its NEXICART-2 Phase 2 trial reached complete remission with NXC-201, a one-time CAR-T cell therapy for AL amyloidosis. The 95% complete response rate is up from 75% in an earlier readout, and all four patients with minimal-residual-disease-negative status have now converted to complete responses.

Updated May 21